

**In the Claims:**

1. (currently amended) ~~Film-shaped~~ A film-shaped administration form for transmucosal administration of at least one active substance substances comprising:

a base mass for producing said administration form, said base mass comprising a solvent or a mixture of solvents, at least one matrix-forming polymer and at least one active substance, said base mass having a pH value, wherein characterized in that

  - [[[-]]] [[the]] said administration form is a dried film, and wherein
  - [[[-]]] [[that]] the pH value of the base mass which is used for the production of for producing said administration form and which comprises a solvent or a mixture of solvents, at least one matrix-forming polymer and at least one active substance was, having been approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied during the production thereof of said administration form, approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied, and wherein
  - [[[-]]] that the said at least one active substance is substance(s) is/are selected from the group consisting of pharmaceutically active substances and aroma substances.
2. (currently amended) ~~Administration~~ The administration form according to claim 1, wherein characterized in that said solvent or at least one solvent of said mixture of solvents is water is used as the solvent or at least as one of the solvents of the mixture of solvents.
3. (currently amended) ~~Administration~~ The administration form according to claim 1, wherein or 2, characterized in that the matrix-forming polymer is selected from the group consisting of polyvinyl alcohol; cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose and hydroxypropyl ethyl cellulose, carboxymethyl cellulose, as well as ethyl or propyl cellulose; starch and starch derivatives; gelatine; polyvinyl pyrrolidones; gum arabic; pullulan; acrylates; dextran; polyacrylic acid; polyacrylates; polyethylene oxide polymers; polyacrylamides; polyethylene glycol; collagen; alginates; pectins; tragacanth; chitosan; alginic acid; arabinogalactan; galactomannan; agar-agar; agarose; carrageenan; and natural gums.
4. (currently amended) ~~Administration~~ The administration form according to claim 1, wherein any one of the preceding claims, characterized in that the polymer portion is 5

to 95%-wt., ~~preferably 15 to 75% wt~~, relative to the dry mass of the administration form.

5. (currently amended) Administration The administration form according to claim 1, wherein any one of the preceding claims, characterized in that the content of said pharmaceutically active substance is 0.1 to 50%-wt., ~~preferably 0.5 to 20% wt~~, relative to the dry mass of the administration form.

6. (currently amended) Administration The administration form according to claim 1, wherein any one of the preceding claims, characterized in that the content of said aroma substance is 0.1 to 20%-wt., ~~preferably 1 to 10% wt~~, relative to the dry mass of the administration form.

7. (currently amended) Administration The administration form according to claim 1, wherein any one of the preceding claims, characterized in that the pH value of the base mass ~~was adjusted having been approximated or adapted~~ to a value in the range between 5 and 9, ~~preferably in the range between 6 and 8.5, and particularly preferably in the range between 6.5 and 8~~.

8. (currently amended) Administration The administration form according to claim 1, wherein any one of the preceding claims, characterized in that the pH value was approximated or adapted ~~adjusted by using a chemical selected from the group consisting of means of~~ sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid ~~and~~  
[~~, or~~] a buffer system, such as, for example, a phosphate buffer.

9. (currently amended) Administration The administration form according to claim 1, wherein said any one of the preceding claims, characterized in that it said administration form is mucoadhesive.

10. (currently amended) Administration The administration form according to claim 1, wherein said any one of the preceding claims, characterized in that it administration form is disintegratable.

11. (currently amended) Administration The administration form according to claim 10, wherein said administration form characterized in that it has become disintegrated ~~disintegrates~~ within 15 minutes min, ~~preferably within 3 min, and particularly preferably within 60 s~~, after having been introduced in an aqueous medium.

12. (currently amended) Administration form according to claim 1, wherein said administration form any one of the preceding claims, characterized in that it administration form is multilayered.

13. (currently amended) Administration The administration form according to claim 1, wherein said administration form any one of the preceding claims, characterized in that it contains at least one or more adjuvants adjuvant selected from the group comprising consisting of filling agents, colourants, flavourings, aroma substances, fragrant substances, emulsifiers, plasticizers, sweeteners, preservatives, permeation-enhancing substances, and antioxidants.

14. (currently amended) Administration The administration form according to claim 13, wherein characterized in that the portion of adjuvants said at least one adjuvant amounts to up to 30%-wt., preferably 1 to 20% wt., relative to the dry mass of the administration form.

15. (currently amended) Use of the administration form according to claim 1 any one of the preceding claims for at use selected from the group of applications consisting of oral, gingival, vaginal [[or]] and rectal application.

16. (currently amended) Process A process for the production of a film-shaped administration form for transmucosal administration of at least one active substance substance, comprising the steps of:

[[ -]] preparing a base mass comprising a solvent or a mixture of solvents, at least one matrix-forming polymer and at least one active substance[[,]] ;

[[ -]] approximating or adapting the pH value of the base mass to the physiological pH value of the mucous membrane to which the administration form is to be applied[[,]] ;

[[ -]] extruding the base mass to form a moist film;[[,]]

[[ -]] drying the moist film;[[,]] and

[[ -]] singularizing the administration form; wherein

[[the]] said at least one active substance substance(s) being is selected from the group consisting of pharmaceutically active substances and aroma substances.

17. (currently amended) Process The process according to claim 16, characterized in that comprising the step of using water is used as the solvent or as at least [[as]] one of the solvents of the mixture of solvents.

18. (currently amended) Process The process according to claim 16, wherein the step of approximating or adapting the pH value of the base mass comprises the step of adjusting or 17, characterized in that the pH value of the base mass is adjusted to a value in the range between 5 and 9, preferably in the range between 6 and 8.5, and particularly preferably in the range between 6.5 and 8.

19. (currently amended) ~~Process~~ The process according to claim 18, wherein the step of adjusting the any one of claims 16 to 18, characterized in that adjustment of the pH value is accomplished by adding a chemical selected from the group consisting of means of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid [[or]] and a buffer system such as, for example, a phosphate buffer.

20. (new) The administration form according to claim 3, wherein said cellulose derivatives are selected from the group consisting of such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl ethyl cellulose, carboxymethyl cellulose, ethyl cellulose and propyl cellulose.

21. (new) The administration form according to claim 4, wherein the polymer portion is 15 to 75%-wt. relative to the dry mass of the administration form.

22. (new) The administration form according to claim 5, wherein the content of said pharmaceutically active substance is 0.5 to 20%-wt. relative to the dry mass of the administration form.

23. (new) The administration form according to claim 6, wherein the content of said aroma substance is 1 to 10%-wt. relative to the dry mass of the administration form.

24. (new) The administration form according to claim 7, wherein the pH value of the base mass was adjusted to a value in the range between 6 and 8.5.

25. (new) The administration form according to claim 24, wherein the pH value of the base mass was adjusted to a value in the range between 6.5 and 8.

26. (new) The administration form according to claim 8, wherein said buffer system is a phosphate buffer.

27. (new) The administration form according to claim 11, wherein said administration form disintegrates within 3 minutes after having been introduced in an aqueous medium.

28. (new) The administration form according to claim 27, wherein said administration form disintegrates within 60 seconds after having been introduced in an aqueous medium.

29. (new) The administration form according to claim 13, wherein the portion of said at least one adjuvant amounts to up to 1 to 20%-wt. relative to the dry mass of the administration form.

30. (new) The process according to claim 18, comprising the step of adjusting the pH value of the base mass to a value in the range between 6 and 8.5.

31. (new) The process according to claim 30, comprising the step of adjusting the pH value of the base mass to a value in the range between 6.5 and 8.
32. (new) The process according to claim 19, wherein said buffer system is a phosphate buffer.